{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,22]],"date-time":"2026-11-22T04:22:56Z","timestamp":1795321376488,"version":"4.10.3"},"reference-count":284,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-021-00269-y","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T04:03:45Z","timestamp":1620878625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2537,"title":["Alzheimer disease"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-066X","authenticated-orcid":false,"given":"David S.","family":"Knopman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Amieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e4el","family":"Ch\u00e9telat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-9401","authenticated-orcid":false,"given":"Bradley T.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-9833","authenticated-orcid":false,"given":"David T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"269_CR1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 10, 844\u2013852 (2014).","journal-title":"Alzheimers Dement."},{"key":"269_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"269_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging and the Alzheimer\u2019s Association workgroup. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"269_CR4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1212\/WNL.0000000000006088","volume":"91","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. Neurology 91, 395\u2013402 (2018).","journal-title":"Neurology"},{"key":"269_CR5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-011-0826-y","volume":"121","author":"PT Nelson","year":"2011","unstructured":"Nelson, P. T. et al. Alzheimer\u2019s disease is not \u201cbrain aging\u201d: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 121, 571\u2013587 (2011).","journal-title":"Acta Neuropathol."},{"key":"269_CR6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.25123","volume":"83","author":"PA Boyle","year":"2018","unstructured":"Boyle, P. A. et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83, 74\u201383 (2018). A clinical-neuropathological analysis of >1,000 persons demonstrating how multiple aetiologies relate to late-life cognition.","journal-title":"Ann. Neurol."},{"key":"269_CR7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.21706","volume":"66","author":"JA Schneider","year":"2009","unstructured":"Schneider, J. A., Arvanitakis, Z., Leurgans, S. E. & Bennett, D. A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200\u2013208 (2009).","journal-title":"Ann. Neurol."},{"key":"269_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi, A., DeCarli, C. & Schneider, J. A. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 134, 171\u2013186 (2017).","journal-title":"Acta Neuropathol."},{"key":"269_CR9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","volume":"77","author":"S Karanth","year":"2020","unstructured":"Karanth, S. et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 77, 1299\u20131307 (2020).","journal-title":"JAMA Neurol."},{"key":"269_CR10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1532-5415.2011.03365.x","volume":"59","author":"H Brodaty","year":"2011","unstructured":"Brodaty, H. et al. The world of dementia beyond 2020. J. Am. Geriatr. Soc. 59, 923\u2013927 (2011).","journal-title":"J. Am. Geriatr. Soc."},{"key":"269_CR11","first-page":"327","volume":"13","author":"YT Wu","year":"2017","unstructured":"Wu, Y. T. et al. The changing prevalence and incidence of dementia over time \u2014 current evidence. Nat. Rev. Neurol. 13, 327\u2013339 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"269_CR12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1504327","volume":"374","author":"CL Satizabal","year":"2016","unstructured":"Satizabal, C. L. et al. Incidence of dementia over three decades in the Framingham Heart Study. N. Engl. J. Med. 374, 523\u2013532 (2016).","journal-title":"N. Engl. J. Med."},{"key":"269_CR13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","volume":"11","author":"Y Stern","year":"2012","unstructured":"Stern, Y. Cognitive reserve in ageing and Alzheimer\u2019s disease. Lancet Neurol. 11, 1006\u20131012 (2012).","journal-title":"Lancet Neurol."},{"key":"269_CR14","volume":"3","author":"SE Tom","year":"2020","unstructured":"Tom, S. E. et al. Trends in incident dementia and early life socieoeconomic status by birth cohort in the adult changes in thought study. JAMA Open 3, e2011094 (2020).","journal-title":"JAMA Open"},{"key":"269_CR15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.0000000000000069","volume":"82","author":"E Kovari","year":"2014","unstructured":"Kovari, E., Herrmann, F. R., Bouras, C. & Gold, G. Amyloid deposition is decreasing in aging brains: an autopsy study of 1,599 older people. Neurology 82, 326\u2013331 (2014).","journal-title":"Neurology"},{"key":"269_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nrl.2016.02.016","volume":"32","author":"H Niu","year":"2017","unstructured":"Niu, H., \u00c1lvarez-\u00c1lvarez, I., Guill\u00e9n-Grima, F. & Aguinaga-Ontoso, I. Prevalence and incidence of Alzheimer\u2019s disease in Europe: a meta-analysis. Neurologia 32, 523\u2013532 (2017).","journal-title":"Neurologia"},{"key":"269_CR17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1212\/WNL.55.2.198","volume":"55","author":"LX Hy","year":"2000","unstructured":"Hy, L. X. & Keller, D. M. Prevalence of AD among whites: a summary by levels of severity. Neurology 55, 198\u2013204 (2000).","journal-title":"Neurology"},{"key":"269_CR18","first-page":"248","volume":"11","author":"C Gillis","year":"2019","unstructured":"Gillis, C., Mirzaei, F., Potashman, M., Ikram, M. A. & Maserejian, N. The incidence of mild cognitive impairment: a systematic review and data synthesis. Alzheimers Dement. 11, 248\u2013256 (2019).","journal-title":"Alzheimers Dement."},{"key":"269_CR19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23931","volume":"74","author":"RC Petersen","year":"2013","unstructured":"Petersen, R. C. et al. Mild cognitive impairment due to Alzheimer\u2019s disease: criteria in the community. Ann. Neurol. 74, 199\u2013208 (2013).","journal-title":"Ann. Neurol."},{"key":"269_CR20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.psym.2015.12.002","volume":"57","author":"EK Degenhardt","year":"2016","unstructured":"Degenhardt, E. K. et al. Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia. Psychosomatics 57, 208\u2013216 (2016).","journal-title":"Psychosomatics"},{"key":"269_CR21","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181\u20132193 (2018).","journal-title":"Brain"},{"key":"269_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-016-0188-8","volume":"8","author":"M Prince","year":"2016","unstructured":"Prince, M. et al. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res. Ther. 8, 23 (2016).","journal-title":"Alzheimers Res. Ther."},{"key":"269_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13195-020-00734-y","volume":"12","author":"S R\u00f6hr","year":"2020","unstructured":"R\u00f6hr, S. et al. Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. Alzheimers Res. Ther. 12, 167 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"269_CR24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology 90, 126\u2013135 (2018).","journal-title":"Neurology"},{"key":"269_CR25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/WNL.0b013e3181f11d85","volume":"75","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Prevalence of mild cognitive impairment is higher in men than in women. The Mayo Clinic Study of Aging. Neurology 75, 889\u2013897 (2010).","journal-title":"Neurology"},{"key":"269_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CLEP.S37929","volume":"6","author":"MM Mielke","year":"2014","unstructured":"Mielke, M. M., Vemuri, P. & Rocca, W. A. Clinical epidemiology of Alzheimer\u2019s disease: assessing sex and gender differences. Clin. Epidemiol. 6, 37\u201348 (2014).","journal-title":"Clin. Epidemiol."},{"key":"269_CR27","doi-asserted-by":"crossref","first-page":"2696.e1","DOI":"10.1016\/j.neurobiolaging.2013.05.028","volume":"34","author":"M Thambisetty","year":"2013","unstructured":"Thambisetty, M., An, Y. & Tanaka, T. Alzheimer\u2019s disease risk genes and the age-at-onset phenotype. Neurobiol. Aging 34, 2696.e1\u20135 (2013).","journal-title":"Neurobiol. Aging"},{"key":"269_CR28","doi-asserted-by":"crossref","first-page":"a006270","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass, C., Kaether, C., Thinakaran, G. & Sisodia, S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"269_CR29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson, T. et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature 488, 96\u201399 (2012).","journal-title":"Nature"},{"key":"269_CR30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","volume":"17","author":"SJ van der Lee","year":"2018","unstructured":"van der Lee, S. J. et al. The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study. Lancet Neurol. 17, 434\u2013444 (2018).","journal-title":"Lancet Neurol."},{"key":"269_CR31","doi-asserted-by":"crossref","first-page":"220.e1","DOI":"10.1016\/j.neurobiolaging.2017.07.001","volume":"59","author":"C Bellenguez","year":"2017","unstructured":"Bellenguez, C. et al. Contribution to Alzheimer\u2019s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol. Aging 59, 220.e1\u2013220.e9 (2017).","journal-title":"Neurobiol. Aging"},{"key":"269_CR32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/acn3.716","volume":"6","author":"G Leonenko","year":"2019","unstructured":"Leonenko, G. et al. Polygenic risk and hazard scores for Alzheimer\u2019s disease prediction. Ann. Clin. Transl. Neurol. 6, 456\u2013465 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"269_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2014.05.041","volume":"83","author":"CM Karch","year":"2014","unstructured":"Karch, C. M., Cruchaga, C. & Goate, A. M. Alzheimer\u2019s disease genetics: from the bench to the clinic. Neuron 83, 11\u201326 (2014).","journal-title":"Neuron"},{"key":"269_CR34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat. Genet. 51, 414\u2013430 (2019).","journal-title":"Nat. Genet."},{"key":"269_CR35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet commission. Lancet 396, 413\u2013446 (2020).","journal-title":"Lancet"},{"key":"269_CR36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamapsychiatry.2017.0660","volume":"74","author":"A Singh-Manoux","year":"2017","unstructured":"Singh-Manoux, A. et al. Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry 74, 712\u2013718 (2017).","journal-title":"JAMA Psychiatry"},{"key":"269_CR37","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamaneurol.2017.1658","volume":"74","author":"RF Gottesman","year":"2017","unstructured":"Gottesman, R. F. et al. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 74, 1246\u20131254 (2017).","journal-title":"JAMA Neurol."},{"key":"269_CR38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2018.11499","volume":"320","author":"C Samieri","year":"2018","unstructured":"Samieri, C. et al. Association of cardiovascular health level in older age with cognitive decline and incident dementia. JAMA 320, 657\u2013664 (2018).","journal-title":"JAMA"},{"key":"269_CR39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2017.3090","volume":"317","author":"RF Gottesman","year":"2017","unstructured":"Gottesman, R. F. et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA 317, 1443\u20131450 (2017).","journal-title":"JAMA"},{"key":"269_CR40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/brain\/awu393","volume":"138","author":"P Vemuri","year":"2015","unstructured":"Vemuri, P. et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 138, 761\u2013771 (2015).","journal-title":"Brain"},{"key":"269_CR41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1126\/science.aau0437","volume":"362","author":"TE Golde","year":"2018","unstructured":"Golde, T. E., DeKosky, S. T. & Galasko, D. Alzheimer\u2019s disease: the right drug, the right time. Science 362, 1250\u20131251 (2018).","journal-title":"Science"},{"key":"269_CR42","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nn.4017","volume":"18","author":"K Herrup","year":"2015","unstructured":"Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18, 794\u2013799 (2015).","journal-title":"Nat. Neurosci."},{"key":"269_CR43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/alz.12157","volume":"16","author":"BV Zlokovic","year":"2020","unstructured":"Zlokovic, B. V. et al. Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement. 16, 1714\u20131733 (2020).","journal-title":"Alzheimers Dement."},{"key":"269_CR44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cercor\/1.1.103","volume":"1","author":"SE Arnold","year":"1991","unstructured":"Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R. & Van Hoesen, G. W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer\u2019s disease. Cereb. Cortex 1, 103\u2013116 (1991). Graphic demonstration of the different regional distributions of A\u03b2 and tau at autopsy.","journal-title":"Cereb. Cortex"},{"key":"269_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"269_CR46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide. Nat. Rev. Mol. Cell Biol. 8, 101\u2013112 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"269_CR47","first-page":"77sr71","volume":"3","author":"DM Holtzman","year":"2011","unstructured":"Holtzman, D. M., Morris, J. C. & Goate, A. M. Alzheimer\u2019s disease: the challenge of the second century. Sci. Transl. Med. 3, 77sr71 (2011).","journal-title":"Sci. Transl. Med."},{"key":"269_CR48","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.R800019200","volume":"283","author":"G Thinakaran","year":"2008","unstructured":"Thinakaran, G. & Koo, E. H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615\u201329619 (2008).","journal-title":"J. Biol. Chem."},{"key":"269_CR49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuron.2019.01.058","volume":"101","author":"C Haass","year":"2019","unstructured":"Haass, C. & Willem, M. Secreted APP modulates synaptic activity: a novel target for therapeutic intervention? Neuron 101, 557\u2013559 (2019).","journal-title":"Neuron"},{"key":"269_CR50","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"JR Cirrito","year":"2005","unstructured":"Cirrito, J. R. et al. Synaptic activity regulates interstitial fluid amyloid-\u03b2 levels in vivo. Neuron 48, 913\u2013922 (2005).","journal-title":"Neuron"},{"key":"269_CR51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","volume":"326","author":"JE Kang","year":"2009","unstructured":"Kang, J. E. et al. Amyloid-\u03b2 dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005\u20131007 (2009).","journal-title":"Science"},{"key":"269_CR52","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.biopsych.2017.11.031","volume":"83","author":"EL Boespflug","year":"2018","unstructured":"Boespflug, E. L. & Iliff, J. J. The emerging relationship between interstitial fluid-cerebrospinal fluid exchange, amyloid-\u03b2, and sleep. Biol. Psychiatry 83, 328\u2013336 (2018).","journal-title":"Biol. Psychiatry"},{"key":"269_CR53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","volume":"82","author":"TL Spires-Jones","year":"2014","unstructured":"Spires-Jones, T. L. & Hyman, B. T. The intersection of amyloid \u03b2 and tau at synapses in Alzheimer\u2019s disease. Neuron 82, 756\u2013771 (2014).","journal-title":"Neuron"},{"key":"269_CR54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/WNL.0000000000005807","volume":"91","author":"EE Benarroch","year":"2018","unstructured":"Benarroch, E. E. Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: emerging mechanisms. Neurology 91, 125\u2013132 (2018).","journal-title":"Neurology"},{"key":"269_CR55","volume":"363","author":"HC Rice","year":"2019","unstructured":"Rice, H. C. et al. Secreted amyloid-\u03b2 precursor protein functions as a GABA(B)R1a ligand to modulate synaptic transmission. Science 363, eaao4827 (2019).","journal-title":"Science"},{"key":"269_CR56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrn.2017.29","volume":"18","author":"UC M\u00fcller","year":"2017","unstructured":"M\u00fcller, U. C., Deller, T. & Korte, M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. 18, 281\u2013298 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"269_CR57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb1717","volume":"12","author":"SA Small","year":"2020","unstructured":"Small, S. A. & Petsko, G. A. Endosomal recycling reconciles the Alzheimer\u2019s disease paradox. Sci. Transl. Med. 12, eabb1717 (2020).","journal-title":"Sci. Transl. Med."},{"key":"269_CR58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-32-9358-8_16","volume":"1184","author":"G Gallardo","year":"2019","unstructured":"Gallardo, G. & Holtzman, D. M. Amyloid-\u03b2 and tau at the crossroads of Alzheimer\u2019s disease. Adv. Exp. Med. Biol. 1184, 187\u2013203 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"Pt A","key":"269_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.018","volume":"76","author":"AM Pooler","year":"2014","unstructured":"Pooler, A. M., Noble, W. & Hanger, D. P. A role for tau at the synapse in Alzheimer\u2019s disease pathogenesis. Neuropharmacology 76(Pt A), 1\u20138 (2014).","journal-title":"Neuropharmacology"},{"key":"269_CR60","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuron.2018.07.039","volume":"99","author":"B Eftekharzadeh","year":"2018","unstructured":"Eftekharzadeh, B. et al. Tau protein disrupts nucleocytoplasmic transport in Alzheimer\u2019s disease. Neuron 99, 925\u2013940.e7 (2018).","journal-title":"Neuron"},{"key":"269_CR61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","volume":"140","author":"SA Kent","year":"2020","unstructured":"Kent, S. A., Spires-Jones, T. L. & Durrant, C. S. The physiological roles of tau and A\u03b2: implications for Alzheimer\u2019s disease pathology and therapeutics. Acta Neuropathol. 140, 417\u2013447 (2020).","journal-title":"Acta Neuropathol."},{"key":"269_CR62","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.20131685","volume":"211","author":"K Yamada","year":"2014","unstructured":"Yamada, K. et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387\u2013393 (2014).","journal-title":"J. Exp. Med."},{"key":"269_CR63","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085\u20131092 (2016).","journal-title":"Nat. Neurosci."},{"key":"269_CR64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","volume":"73","author":"A de Calignon","year":"2012","unstructured":"de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer\u2019s disease. Neuron 73, 685\u2013697 (2012).","journal-title":"Neuron"},{"key":"269_CR65","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin, S. et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat. Med. 26, 1256\u20131263 (2020). A clinical-neuropathological-molecular demonstration of how post-translational modifications of tau might play a role in the rate of clinical progression.","journal-title":"Nat. Med."},{"key":"269_CR66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017).","journal-title":"Nature"},{"key":"269_CR67","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1172\/JCI138179","volume":"130","author":"M Gratuze","year":"2020","unstructured":"Gratuze, M. et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest. 130, 4954\u20134968 (2020).","journal-title":"J. Clin. Invest."},{"key":"269_CR68","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1084\/jem.20190980","volume":"216","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 216, 2546\u20132561 (2019).","journal-title":"J. Exp. Med."},{"key":"269_CR69","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960\u2013969 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"269_CR70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"269_CR71","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte, A. et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology 52, 1158\u20131165 (1999).","journal-title":"Neurology"},{"key":"269_CR72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann. Neurol. 45, 358\u2013368 (1999).","journal-title":"Ann. Neurol."},{"key":"269_CR73","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0531-5565(02)00141-9","volume":"37","author":"A Delacourte","year":"2002","unstructured":"Delacourte, A. et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp. Gerontol. 37, 1291\u20131296 (2002).","journal-title":"Exp. Gerontol."},{"key":"269_CR74","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766 (2014).","journal-title":"Acta Neuropathol."},{"key":"269_CR75","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack","year":"2019","unstructured":"Jack, C. R. et al. The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain 142, 3230\u20133242 (2019).","journal-title":"Brain"},{"key":"269_CR76","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915\u2013924 (2019).","journal-title":"JAMA Neurol."},{"key":"269_CR77","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"269_CR78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford, J. et al. New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol. 20, 222\u2013234 (2021).","journal-title":"Lancet Neurol."},{"key":"269_CR79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim, J., Basak, J. M. & Holtzman, D. M. The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron 63, 287\u2013303 (2009).","journal-title":"Neuron"},{"key":"269_CR80","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1194\/jlr.R075481","volume":"58","author":"TV Huynh","year":"2017","unstructured":"Huynh, T. V., Davis, A. A., Ulrich, J. D., Holtzman, D. M. & Apolipoprotein, E. and Alzheimer\u2019s disease: the influence of apolipoprotein E on amyloid-\u03b2 and other amyloidogenic proteins. J. Lipid Res. 58, 824\u2013836 (2017).","journal-title":"J. Lipid Res."},{"key":"269_CR81","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman, E. M. et al. Fibrillar amyloid-\u03b2 burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 106, 6820\u20136825 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"269_CR82","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaneurol.2014.4821","volume":"72","author":"CR Jack Jr.","year":"2015","unstructured":"Jack, C. R. Jr. et al. Age, sex, and APOE e4 effects on memory, brain structure, and \u03b2-amyloid across the adult life span. JAMA Neurol. 72, 511\u2013519 (2015).","journal-title":"JAMA Neurol."},{"key":"269_CR83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"R van der Kant","year":"2020","unstructured":"van der Kant, R., Goldstein, L. S. B. & Ossenkoppele, R. Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci. 21, 21\u201335 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"269_CR84","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","volume":"60","author":"SA Small","year":"2008","unstructured":"Small, S. A. & Duff, K. Linking A\u03b2 and tau in late-onset Alzheimer\u2019s disease: a dual pathway hypothesis. Neuron 60, 534\u2013542 (2008).","journal-title":"Neuron"},{"key":"269_CR85","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat. Neurosci. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci."},{"key":"269_CR86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0969-9961(03)00084-6","volume":"14","author":"MA Kurt","year":"2003","unstructured":"Kurt, M. A., Davies, D. C., Kidd, M., Duff, K. & Howlett, D. R. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 14, 89\u201397 (2003).","journal-title":"Neurobiol. Dis."},{"key":"269_CR87","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnen\/60.8.753","volume":"60","author":"R Le","year":"2001","unstructured":"Le, R. et al. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60, 753\u2013758 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"269_CR88","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","volume":"22","author":"CEG Leyns","year":"2019","unstructured":"Leyns, C. E. G. et al. TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22, 1217\u20131222 (2019).","journal-title":"Nat. Neurosci."},{"key":"269_CR89","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tins.2017.08.003","volume":"40","author":"SA Small","year":"2017","unstructured":"Small, S. A., Simoes-Spassov, S., Mayeux, R. & Petsko, G. A. Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer\u2019s disease. Trends Neurosci. 40, 592\u2013602 (2017).","journal-title":"Trends Neurosci."},{"key":"269_CR90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.01.021","volume":"43","author":"RA Nixon","year":"2011","unstructured":"Nixon, R. A. & Yang, D. S. Autophagy failure in Alzheimer\u2019s disease\u2013locating the primary defect. Neurobiol. Dis. 43, 38\u201345 (2011).","journal-title":"Neurobiol. Dis."},{"key":"269_CR91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","volume":"17","author":"JJ Palop","year":"2016","unstructured":"Palop, J. J. & Mucke, L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 17, 777\u2013792 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"269_CR92","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572\u2013580 (1991).","journal-title":"Ann. Neurol."},{"key":"269_CR93","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann. Neurol. 27, 457\u2013464 (1990). A real-time demonstration of a close correspondence between synapse loss and degree of cognitive impairment in brain biopsies from patients with AD.","journal-title":"Ann. Neurol."},{"key":"269_CR94","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1523\/JNEUROSCI.1879-05.2005","volume":"25","author":"TL Spires","year":"2005","unstructured":"Spires, T. L. et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278\u20137287 (2005).","journal-title":"J. Neurosci."},{"key":"269_CR95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-017-0169-9","volume":"12","author":"M Arbel-Ornath","year":"2017","unstructured":"Arbel-Ornath, M. et al. Soluble oligomeric amyloid-\u03b2 induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol. Neurodegener. 12, 27 (2017).","journal-title":"Mol. Neurodegener."},{"key":"269_CR96","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou, L. et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 8, 15295 (2017).","journal-title":"Nat. Commun."},{"key":"269_CR97","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF00293464","volume":"81","author":"E Masliah","year":"1991","unstructured":"Masliah, E., Hansen, L., Albright, T., Mallory, M. & Terry, R. D. Immunoelectron microscopic study of synaptic pathology in Alzheimer\u2019s disease. Acta Neuropathol. 81, 428\u2013433 (1991).","journal-title":"Acta Neuropathol."},{"key":"269_CR98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-015-0232-0","volume":"3","author":"CM Henstridge","year":"2015","unstructured":"Henstridge, C. M. et al. Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathol. Commun. 3, 53 (2015).","journal-title":"Acta Neuropathol. Commun."},{"key":"269_CR99","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lleo","year":"2019","unstructured":"Lleo, A. et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s Disease cerebrospinal fluid. Mol. Cell Proteom. 18, 546\u2013560 (2019).","journal-title":"Mol. Cell Proteom."},{"key":"269_CR100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fnins.2018.00267","volume":"12","author":"SL DeVos","year":"2018","unstructured":"DeVos, S. L. et al. Synaptic tau seeding precedes tau pathology in human Alzheimer\u2019s disease brain. Front. Neurosci. 12, 267 (2018).","journal-title":"Front. Neurosci."},{"key":"269_CR101","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337\u2013351 (2007).","journal-title":"Neuron"},{"key":"269_CR102","doi-asserted-by":"crossref","first-page":"8631","DOI":"10.1073\/pnas.1708106114","volume":"114","author":"AD Keskin","year":"2017","unstructured":"Keskin, A. D. et al. BACE inhibition-dependent repair of Alzheimer\u2019s pathophysiology. Proc. Natl Acad. Sci. USA 114, 8631\u20138636 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"269_CR103","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1126\/science.1162844","volume":"321","author":"MA Busche","year":"2008","unstructured":"Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer\u2019s disease. Science 321, 1686\u20131689 (2008).","journal-title":"Science"},{"key":"269_CR104","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuron.2008.06.008","volume":"59","author":"KV Kuchibhotla","year":"2008","unstructured":"Kuchibhotla, K. V. et al. A\u03b2 plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214\u2013225 (2008).","journal-title":"Neuron"},{"key":"269_CR105","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.neuron.2015.01.025","volume":"85","author":"N Menkes-Caspi","year":"2015","unstructured":"Menkes-Caspi, N. et al. Pathological tau disrupts ongoing network activity. Neuron 85, 959\u2013966 (2015).","journal-title":"Neuron"},{"key":"269_CR106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41593-018-0289-8","volume":"22","author":"MA Busche","year":"2019","unstructured":"Busche, M. A. et al. Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in vivo. Nat. Neurosci. 22, 57\u201364 (2019).","journal-title":"Nat. Neurosci."},{"key":"269_CR107","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cne.902520306","volume":"252","author":"KJ Anderson","year":"1986","unstructured":"Anderson, K. J., Scheff, S. W. & DeKosky, S. T. Reactive synaptogenesis in hippocampal area CA1 of aged and young adult rats. J. Comp. Neurol. 252, 374\u2013384 (1986).","journal-title":"J. Comp. Neurol."},{"key":"269_CR108","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0168-0102(86)90062-3","volume":"3","author":"JW Geddes","year":"1986","unstructured":"Geddes, J. W. & Cotman, C. W. Plasticity in hippocampal excitatory amino acid receptors in Alzheimer\u2019s disease. Neurosci. Res. 3, 672\u2013678 (1986).","journal-title":"Neurosci. Res."},{"key":"269_CR109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.410210307","volume":"21","author":"BT Hyman","year":"1987","unstructured":"Hyman, B. T., Kromer, L. J. & Van Hoesen, G. W. Reinnervation of the hippocampal perforant pathway zone in Alzheimer\u2019s disease. Ann. Neurol. 21, 259\u2013267 (1987).","journal-title":"Ann. Neurol."},{"key":"269_CR110","volume":"7","author":"L Liu","year":"2012","unstructured":"Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012).","journal-title":"PLoS ONE"},{"key":"269_CR111","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch, J. N. et al. LRP1 is a master regulator of tau uptake and spread. Nature 580, 381\u2013385 (2020).","journal-title":"Nature"},{"key":"269_CR112","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0092-8674(95)90320-8","volume":"82","author":"MZ Kounnas","year":"1995","unstructured":"Kounnas, M. Z. et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted \u03b2-amyloid precursor protein and mediates its degradation. Cell 82, 331\u2013340 (1995).","journal-title":"Cell"},{"key":"269_CR113","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","volume":"11","author":"GW Rebeck","year":"1993","unstructured":"Rebeck, G. W., Reiter, J. S., Strickland, D. K. & Hyman, B. T. Apolipoprotein E in sporadic Alzheimer\u2019s disease: allelic variation and receptor interactions. Neuron 11, 575\u2013580 (1993).","journal-title":"Neuron"},{"key":"269_CR114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-neuro-070918-050306","volume":"42","author":"DK Wilton","year":"2019","unstructured":"Wilton, D. K., Dissing-Olesen, L. & Stevens, B. Neuron-glia signaling in synapse elimination. Annu. Rev. Neurosci. 42, 107\u2013127 (2019).","journal-title":"Annu. Rev. Neurosci."},{"key":"269_CR115","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.3232","volume":"19","author":"RA Nixon","year":"2013","unstructured":"Nixon, R. A. The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983\u2013997 (2013).","journal-title":"Nat. Med."},{"key":"269_CR116","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuron.2017.01.022","volume":"93","author":"FM Menzies","year":"2017","unstructured":"Menzies, F. M. et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93, 1015\u20131034 (2017).","journal-title":"Neuron"},{"key":"269_CR117","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1096\/fj.201700359","volume":"31","author":"RA Nixon","year":"2017","unstructured":"Nixon, R. A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer\u2019s disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729\u20132743 (2017).","journal-title":"FASEB J."},{"key":"269_CR118","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1523\/JNEUROSCI.3505-17.2018","volume":"38","author":"M Shehata","year":"2018","unstructured":"Shehata, M. et al. Autophagy enhances memory erasure through synaptic destabilization. J. Neurosci. 38, 3809\u20133822 (2018).","journal-title":"J. Neurosci."},{"key":"269_CR119","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cub.2018.12.021","volume":"29","author":"M Glatigny","year":"2019","unstructured":"Glatigny, M. et al. Autophagy is required for memory formation and reverses age-related memory decline. Curr. Biol. 29, 435\u2013448.e8 (2019).","journal-title":"Curr. Biol."},{"key":"269_CR120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0002-9440(10)64538-5","volume":"157","author":"AM Cataldo","year":"2000","unstructured":"Cataldo, A. M. et al. Endocytic pathway abnormalities precede amyloid \u03b2 deposition in sporadic Alzheimer\u2019s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277\u2013286 (2000).","journal-title":"Am. J. Pathol."},{"key":"269_CR121","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13024-019-0323-7","volume":"14","author":"ZP Van Acker","year":"2019","unstructured":"Van Acker, Z. P., Bretou, M. & Annaert, W. Endo-lysosomal dysregulations and late-onset Alzheimer\u2019s disease: impact of genetic risk factors. Mol. Neurodegener. 14, 20 (2019).","journal-title":"Mol. Neurodegener."},{"key":"269_CR122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-020-00649-8","volume":"12","author":"CN Suire","year":"2020","unstructured":"Suire, C. N. et al. Cathepsin D regulates cerebral A\u03b242\/40 ratios via differential degradation of A\u03b242 and A\u03b240. Alzheimers Res. Ther. 12, 80 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"269_CR123","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuron.2019.07.010","volume":"104","author":"D Kwart","year":"2019","unstructured":"Kwart, D. et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP \u03b2-CTFs, not A\u03b2. Neuron 104, 256\u2013270.e5 (2019). Evidence from induced pluripotent stem cells on the critical role of endosomal dysregulation in the pathogenesis of A\u03b2 and tau-induced disease.","journal-title":"Neuron"},{"key":"269_CR124","doi-asserted-by":"crossref","first-page":"108420","DOI":"10.1016\/j.celrep.2020.108420","volume":"33","author":"A Pensalfini","year":"2020","unstructured":"Pensalfini, A. et al. Endosomal dysfunction induced by directly over-activating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer\u2019s disease. Cell Rep. 33, 108420 (2020).","journal-title":"Cell Rep."},{"key":"269_CR125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00401-016-1577-6","volume":"132","author":"I Lauritzen","year":"2016","unstructured":"Lauritzen, I. et al. Intraneuronal aggregation of the \u03b2-CTF fragment of APP (C99) induces A\u03b2-independent lysosomal-autophagic pathology. Acta Neuropathol. 132, 257\u2013276 (2016).","journal-title":"Acta Neuropathol."},{"key":"269_CR126","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.celrep.2015.07.050","volume":"12","author":"JH Lee","year":"2015","unstructured":"Lee, J. H. et al. Presenilin 1 maintains lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 12, 1430\u20131444 (2015).","journal-title":"Cell Rep."},{"key":"269_CR127","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.jmb.2020.02.021","volume":"432","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. \u03b22-adrenergic agonists rescue lysosome acidification and function in PSEN1 deficiency by reversing defective ER-to-lysosome delivery of ClC-7. J. Mol. Biol. 432, 2633\u20132650 (2020).","journal-title":"J. Mol. Biol."},{"key":"269_CR128","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00018-015-1886-2","volume":"72","author":"N Morel","year":"2015","unstructured":"Morel, N. & Poea-Guyon, S. The membrane domain of vacuolar H+ATPase: a crucial player in neurotransmitter exocytotic release. Cell. Mol. Life Sci. 72, 2561\u20132573 (2015).","journal-title":"Cell. Mol. Life Sci."},{"key":"269_CR129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12576-016-0462-3","volume":"67","author":"H Higashida","year":"2017","unstructured":"Higashida, H., Yokoyama, S., Tsuji, C. & Muramatsu, S. I. Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson\u2019s, Alzheimer\u2019s, and psychiatric diseases. J. Physiol. Sci. 67, 11\u201317 (2017).","journal-title":"J. Physiol. Sci."},{"key":"269_CR130","first-page":"603","volume":"117","author":"O El Far","year":"2011","unstructured":"El Far, O. & Seagar, M. A role for V-ATPase subunits in synaptic vesicle fusion? J. Neurochem. 117, 603\u2013612 (2011).","journal-title":"J. Neurochem."},{"key":"269_CR131","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/brain\/awy289","volume":"142","author":"KY Peng","year":"2019","unstructured":"Peng, K. Y. et al. Apolipoprotein E4 genotype compromises brain exosome production. Brain 142, 163\u2013175 (2019).","journal-title":"Brain"},{"key":"269_CR132","doi-asserted-by":"crossref","first-page":"19986","DOI":"10.1074\/jbc.M109.036798","volume":"285","author":"RQ Liu","year":"2010","unstructured":"Liu, R. Q. et al. Membrane localization of \u03b2-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization. J. Biol. Chem. 285, 19986\u201319996 (2010).","journal-title":"J. Biol. Chem."},{"key":"269_CR133","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-cellbio-100818-125300","volume":"35","author":"H Morishita","year":"2019","unstructured":"Morishita, H. & Mizushima, N. Diverse cellular roles of autophagy. Annu. Rev. Cell Dev. Biol. 35, 453\u2013475 (2019).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"269_CR134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","volume":"176","author":"B Levine","year":"2019","unstructured":"Levine, B. & Kroemer, G. Biological functions of autophagy genes: a disease perspective. Cell 176, 11\u201342 (2019).","journal-title":"Cell"},{"key":"269_CR135","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1080\/15548627.2016.1239003","volume":"12","author":"M Bordi","year":"2016","unstructured":"Bordi, M. et al. Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy 12, 2467\u20132483 (2016).","journal-title":"Autophagy"},{"key":"269_CR136","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbadis.2009.10.006","volume":"1802","author":"PI Moreira","year":"2010","unstructured":"Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A. & Perry, G. Mitochondrial dysfunction is a trigger of Alzheimer\u2019s disease pathophysiology. Biochim. Biophys. Acta 1802, 2\u201310 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"269_CR137","doi-asserted-by":"crossref","first-page":"140443","DOI":"10.1016\/j.bbapap.2020.140443","volume":"1868","author":"RA Nixon","year":"2020","unstructured":"Nixon, R. A. The aging lysosome: an essential catalyst for late-onset neurodegenerative diseases. Biochim. Biophys. Acta Proteins Proteom. 1868, 140443 (2020).","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"269_CR138","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/jnc.13935","volume":"140","author":"LS Whyte","year":"2017","unstructured":"Whyte, L. S., Lau, A. A., Hemsley, K. M., Hopwood, J. J. & Sargeant, T. J. Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer\u2019s disease? J. Neurochem. 140, 703\u2013717 (2017).","journal-title":"J. Neurochem."},{"key":"269_CR139","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nbd.2014.07.011","volume":"71","author":"A Pensalfini","year":"2014","unstructured":"Pensalfini, A. et al. Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol. Dis. 71, 53\u201361 (2014).","journal-title":"Neurobiol. Dis."},{"key":"269_CR140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/brain\/awn312","volume":"132","author":"R Adalbert","year":"2009","unstructured":"Adalbert, R. et al. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132, 402\u2013416 (2009).","journal-title":"Brain"},{"key":"269_CR141","doi-asserted-by":"crossref","first-page":"a008839","DOI":"10.1101\/cshperspect.a008839","volume":"4","author":"RA Nixon","year":"2012","unstructured":"Nixon, R. A. & Yang, D. S. Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb. Perspect. Biol. 4, a008839 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"269_CR142","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/1673-5374.264444","volume":"15","author":"H Nakanishi","year":"2020","unstructured":"Nakanishi, H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regenerat. Res. 15, 25\u201329 (2020).","journal-title":"Neural Regenerat. Res."},{"key":"269_CR143","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainresbull.2018.02.014","volume":"139","author":"JR Lowry","year":"2018","unstructured":"Lowry, J. R. & Klegeris, A. Emerging roles of microglial cathepsins in neurodegenerative disease. Brain Res. Bull. 139, 144\u2013156 (2018).","journal-title":"Brain Res. Bull."},{"key":"269_CR144","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1172\/JCI90606","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus, H. & Heneka, M. T. Microglia in Alzheimer\u2019s disease. J. Clin. Invest. 127, 3240\u20133249 (2017).","journal-title":"J. Clin. Invest."},{"key":"269_CR145","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nri3532","volume":"13","author":"V Deretic","year":"2013","unstructured":"Deretic, V., Saitoh, T. & Akira, S. Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol. 13, 722\u2013737 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"269_CR146","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.4161\/auto.29647","volume":"10","author":"MH Cho","year":"2014","unstructured":"Cho, M. H. et al. Autophagy in microglia degrades extracellular \u03b2-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy 10, 1761\u20131775 (2014).","journal-title":"Autophagy"},{"key":"269_CR147","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1523\/JNEUROSCI.2110-16.2016","volume":"37","author":"TR Jay","year":"2017","unstructured":"Jay, T. R. et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer\u2019s disease. J. Neurosci. 37, 637\u2013647 (2017).","journal-title":"J. Neurosci."},{"key":"269_CR148","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","volume":"108","author":"JW Lewcock","year":"2020","unstructured":"Lewcock, J. W. et al. Emerging microglia biology defines novel therapeutic approaches for Alzheimer\u2019s disease. Neuron 108, 801\u2013821 (2020).","journal-title":"Neuron"},{"key":"269_CR149","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/mp.2016.103","volume":"22","author":"HJ Kim","year":"2017","unstructured":"Kim, H. J. et al. Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. Mol. Psychiatry 22, 1576\u20131584 (2017).","journal-title":"Mol. Psychiatry"},{"key":"269_CR150","doi-asserted-by":"crossref","first-page":"a006379","DOI":"10.1101\/cshperspect.a006379","volume":"2","author":"T Saido","year":"2012","unstructured":"Saido, T. & Leissring, M. A. Proteolytic degradation of amyloid \u03b2-protein. Cold Spring Harb. Perspect. Med. 2, a006379 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"269_CR151","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","volume":"17","author":"MK Rasmussen","year":"2018","unstructured":"Rasmussen, M. K., Mestre, H. & Nedergaard, M. The glymphatic pathway in neurological disorders. Lancet Neurol. 17, 1016\u20131024 (2018).","journal-title":"Lancet Neurol."},{"key":"269_CR152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1440.011","volume":"1124","author":"RL Buckner","year":"2008","unstructured":"Buckner, R. L., Andrews-Hanna, J. R. & Schacter, D. L. The brain\u2019s default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 1124, 1\u201338 (2008). Demonstration of the relationship between the default mode network and amyloid accumulation.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"269_CR153","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1073\/pnas.0308627101","volume":"101","author":"MD Greicius","year":"2004","unstructured":"Greicius, M. D., Srivastava, G., Reiss, A. L. & Menon, V. Default-mode network activity distinguishes Alzheimer\u2019s disease from healthy aging: evidence from functional MRI. Proc. Natl Acad. Sci. USA 101, 4637\u20134642 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"269_CR154","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1523\/JNEUROSCI.5062-08.2009","volume":"29","author":"RL Buckner","year":"2009","unstructured":"Buckner, R. L. et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer\u2019s disease. J. Neurosci. 29, 1860\u20131873 (2009).","journal-title":"J. Neurosci."},{"key":"269_CR155","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.neurobiolaging.2011.06.007","volume":"33","author":"F Agosta","year":"2012","unstructured":"Agosta, F. et al. Resting state fMRI in Alzheimer\u2019s disease: beyond the default mode network. Neurobiol. Aging 33, 1564\u20131578 (2012).","journal-title":"Neurobiol. Aging"},{"key":"269_CR156","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.neurobiolaging.2014.12.013","volume":"36","author":"JL Whitwell","year":"2015","unstructured":"Whitwell, J. L. et al. Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer\u2019s dementia. Neurobiol. Aging 36, 1245\u20131252 (2015).","journal-title":"Neurobiol. Aging"},{"key":"269_CR157","doi-asserted-by":"crossref","first-page":"fcaa068","DOI":"10.1093\/braincomms\/fcaa068","volume":"2","author":"RA Townley","year":"2020","unstructured":"Townley, R. A. et al. Progressive dysexecutive syndrome due to Alzheimer\u2019s disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2, fcaa068 (2020).","journal-title":"Brain Commun."},{"key":"269_CR158","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14159-1","volume":"11","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier, N. et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer\u2019s disease. Nat. Commun. 11, 347 (2020).","journal-title":"Nat. Commun."},{"key":"269_CR159","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhaa319","author":"I Sintini","year":"2020","unstructured":"Sintini, I. et al. Tau and amyloid relationships with resting-state functional connectivity in atypical Alzheimer\u2019s disease. Cereb. Cortex https:\/\/doi.org\/10.1093\/cercor\/bhaa319 (2020).","journal-title":"Cereb. Cortex"},{"key":"269_CR160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cortex.2017.09.018","volume":"97","author":"DT Jones","year":"2017","unstructured":"Jones, D. T. et al. Tau, amyloid, and cascading network failure across the Alzheimer\u2019s disease spectrum. Cortex 97, 143\u2013159 (2017).","journal-title":"Cortex"},{"key":"269_CR161","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamaneurol.2017.0263","volume":"74","author":"J Sepulcre","year":"2017","unstructured":"Sepulcre, J. et al. Hierarchical organization of tau and amyloid deposits in the cerebral cortex. JAMA Neurol. 74, 813\u2013820 (2017).","journal-title":"JAMA Neurol."},{"key":"269_CR162","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1212\/01.wnl.0000435556.21319.e4","volume":"81","author":"CR Jack Jr.","year":"2013","unstructured":"Jack, C. R. Jr. et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732\u20131740 (2013).","journal-title":"Neurology"},{"key":"269_CR163","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/2013.jamaneurol.286","volume":"70","author":"HD Protas","year":"2013","unstructured":"Protas, H. D. et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 70, 320\u2013325 (2013).","journal-title":"JAMA Neurol."},{"key":"269_CR164","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd1327","volume":"6","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier, N. et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer\u2019s disease. Sci. Adv. 6, eabd1327 (2020). Analysis showing how regional tau expansion follows connectivity patterns.","journal-title":"Sci. Adv."},{"key":"269_CR165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/156720512801322582","volume":"9","author":"G D\u2019Onofrio","year":"2012","unstructured":"D\u2019Onofrio, G. et al. Neuropsychiatric symptoms and functional status in Alzheimer\u2019s disease and vascular dementia patients. Curr. Alzheimer Res. 9, 759\u2013771 (2012).","journal-title":"Curr. Alzheimer Res."},{"key":"269_CR166","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/brain\/aws327","volume":"136","author":"M Lehmann","year":"2013","unstructured":"Lehmann, M. et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer\u2019s disease. Brain 136, 844\u2013858 (2013).","journal-title":"Brain"},{"key":"269_CR167","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","volume":"13","author":"SJ Crutch","year":"2017","unstructured":"Crutch, S. J. et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 13, 870\u2013884 (2017).","journal-title":"Alzheimers Dement."},{"key":"269_CR168","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/01.wnl.0000320506.79811.da","volume":"71","author":"ML Gorno-Tempini","year":"2008","unstructured":"Gorno-Tempini, M. L. et al. The logopenic\/phonological variant of primary progressive aphasia. Neurology 71, 1227\u20131234 (2008).","journal-title":"Neurology"},{"key":"269_CR169","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.25333","volume":"84","author":"D Bergeron","year":"2018","unstructured":"Bergeron, D. et al. Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia. Ann. Neurol. 84, 729\u2013740 (2018).","journal-title":"Ann. Neurol."},{"key":"269_CR170","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/brain\/awv191","volume":"138","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele, R. et al. The behavioural\/dysexecutive variant of Alzheimer\u2019s disease: clinical, neuroimaging and pathological features. Brain 138, 2732\u20132749 (2015).","journal-title":"Brain"},{"key":"269_CR171","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray, M. E. et al. Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10, 785\u2013796 (2011).","journal-title":"Lancet Neurol."},{"key":"269_CR172","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1001\/archinte.163.18.2219","volume":"163","author":"AM Clarfield","year":"2003","unstructured":"Clarfield, A. M. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch. Intern. Med. 163, 2219\u20132229 (2003).","journal-title":"Arch. Intern. Med."},{"key":"269_CR173","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at national institute on aging Alzheimer disease centers, 2005-2010. J. Neuropathol. Exp. Neurol. 71, 266\u2013273 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"269_CR174","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"269_CR175","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477 (2011).","journal-title":"Brain"},{"key":"269_CR176","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014 (2011).","journal-title":"Neurology"},{"key":"269_CR177","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/awy049","volume":"141","author":"H Botha","year":"2018","unstructured":"Botha, H. et al. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain 141, 1201\u20131217 (2018).","journal-title":"Brain"},{"key":"269_CR178","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2019.22527","volume":"323","author":"RC Petersen","year":"2020","unstructured":"Petersen, R. C. & Yaffe, K. Issues and questions surrounding screening for cognitive impairment in older patients. JAMA 323, 722\u2013724 (2020).","journal-title":"JAMA"},{"key":"269_CR179","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.22258","volume":"323","author":"CD Patnode","year":"2020","unstructured":"Patnode, C. D. et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US Preventive Services TaskFforce. JAMA 323, 764\u2013785 (2020).","journal-title":"JAMA"},{"key":"269_CR180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"269_CR181","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Chetelat","year":"2020","unstructured":"Chetelat, G. et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u201ds disease and other dementias. Lancet Neurol. 19, 951\u2013962 (2020).","journal-title":"Lancet Neurol."},{"key":"269_CR182","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"269_CR183","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CRJ Jack","year":"2011","unstructured":"Jack, C. R. J. et al. Introduction to revised criteria for the diagnosis of Alzheimer\u2019s disease: National Institute on Aging and the Alzheimer Association Workgroups. Alzheimer\u2019s Dement. 7, 257\u2013262 (2011).","journal-title":"Alzheimer\u2019s Dement."},{"key":"269_CR184","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neurobiolaging.2016.06.003","volume":"46","author":"DS Knopman","year":"2016","unstructured":"Knopman, D. S. et al. Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiol. Aging 46, 32\u201342 (2016).","journal-title":"Neurobiol. Aging"},{"key":"269_CR185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pscychresns.2015.08.014","volume":"247","author":"J Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der, J. & Pantel, J. Neuroimaging of hippocampal atrophy in early recognition of Alzheimer\u2019s disease\u2013a critical appraisal after two decades of research. Psychiatry Res. Neuroimaging 247, 71\u201378 (2016).","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"269_CR186","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-019-02036-6","volume":"138","author":"C Petersen","year":"2019","unstructured":"Petersen, C. et al. Alzheimer\u2019s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathol. 138, 597\u2013612 (2019).","journal-title":"Acta Neuropathol."},{"key":"269_CR187","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1474-4422(06)70550-6","volume":"5","author":"BH Ridha","year":"2006","unstructured":"Ridha, B. H. et al. Tracking atrophy progression in familial Alzheimer\u2019s disease: a serial MRI study. Lancet Neurol. 5, 828\u2013834 (2006).","journal-title":"Lancet Neurol."},{"key":"269_CR188","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg, S. M. et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat. Rev. Neurol. 16, 30\u201342 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"269_CR189","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1212\/WNL.0000000000006780","volume":"92","author":"J Graff-Radford","year":"2019","unstructured":"Graff-Radford, J. et al. Cerebral microbleeds: prevalence and relationship to amyloid burden. Neurology 92, e253\u2013e262 (2019).","journal-title":"Neurology"},{"key":"269_CR190","volume":"12","author":"X Li","year":"2017","unstructured":"Li, X. et al. The significant effects of cerebral microbleeds on cognitive dysfunction: an updated meta-analysis. PLoS ONE 12, e0185145 (2017).","journal-title":"PLoS ONE"},{"key":"269_CR191","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.nicl.2014.03.005","volume":"4","author":"R Laforce Jr.","year":"2014","unstructured":"Laforce, R. Jr. et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer\u2019s pathology. Neuroimage Clin. 4, 508\u2013516 (2014).","journal-title":"Neuroimage Clin."},{"key":"269_CR192","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1212\/WNL.0000000000001209","volume":"84","author":"A Caroli","year":"2015","unstructured":"Caroli, A. et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84, 508\u2013515 (2015).","journal-title":"Neurology"},{"key":"269_CR193","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/acn3.782","volume":"6","author":"L Iaccarino","year":"2019","unstructured":"Iaccarino, L., Sala, A. & Perani, D. Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET. Ann. Clin. Transl. Neurol. 6, 1113\u20131120 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"269_CR194","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne, V. L., Dor\u00e9, V., Burnham, S. C., Masters, C. L. & Rowe, C. C. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 14, 225\u2013236 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"269_CR195","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"key":"269_CR196","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/brain\/awv050","volume":"138","author":"ME Murray","year":"2015","unstructured":"Murray, M. E. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer\u2019s disease spectrum. Brain 138, 1370\u20131381 (2015).","journal-title":"Brain"},{"key":"269_CR197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1\u201315.e1\u20134 (2015).","journal-title":"Alzheimers Dement."},{"key":"269_CR198","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau, S. M. et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann. Neurol. 74, 826\u2013836 (2013).","journal-title":"Ann. Neurol."},{"key":"269_CR199","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy, A. et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study. Brain 139, 2540\u20132553 (2016).","journal-title":"Brain"},{"key":"269_CR200","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe, M. J. et al. In vivo staging of regional amyloid deposition. Neurology 89, 2031\u20132038 (2017).","journal-title":"Neurology"},{"key":"269_CR201","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"WJ Jagust","year":"2021","unstructured":"Jagust, W. J. & Landau, S. M. Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer\u2019s disease. Neurology 96, e1347\u2013e1357 (2021).","journal-title":"Neurology"},{"key":"269_CR202","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","volume":"76","author":"CR Jack Jr.","year":"2019","unstructured":"Jack, C. R. Jr. et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using THE National Institute on Aging-Alzheimer\u2019s association research framework. JAMA Neurol. 76, 1174\u20131183 (2019).","journal-title":"JAMA Neurol."},{"key":"269_CR203","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson, K. A. et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer\u2019s association. J. Nucl. Med. 54, 476\u2013490 (2013).","journal-title":"J. Nucl. Med."},{"key":"269_CR204","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286\u20131294 (2019). A very large pragmatic trial of the value of A\u03b2 imaging in clinical dementia practice.","journal-title":"JAMA"},{"key":"269_CR205","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde, A. et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 75, 1062\u20131070 (2018).","journal-title":"JAMA Neurol."},{"key":"269_CR206","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3988\/jcn.2020.16.2.202","volume":"16","author":"HJ Jeong","year":"2020","unstructured":"Jeong, H. J. et al. [18F]THK5351 PET imaging in patients with mild cognitive impairment. J. Clin. Neurol. 16, 202\u2013214 (2020).","journal-title":"J. Clin. Neurol."},{"key":"269_CR207","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818\u20132830 (2020).","journal-title":"Brain"},{"key":"269_CR208","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"269_CR209","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018). Demonstration of the remarkable specificity of an elevated tau PET signal outside of the medial temporal lobe for persons with elevated A\u03b2.","journal-title":"JAMA"},{"key":"269_CR210","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","volume":"91","author":"AJ Aschenbrenner","year":"2018","unstructured":"Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C. & Hassenstab, J. J. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91, e859\u2013e866 (2018).","journal-title":"Neurology"},{"key":"269_CR211","doi-asserted-by":"crossref","first-page":"338ra366","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier, M. R. et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci. Transl. Med. 8, 338ra366 (2016).","journal-title":"Sci. Transl. Med."},{"key":"269_CR212","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.25406","volume":"85","author":"TM Harrison","year":"2019","unstructured":"Harrison, T. M. et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann. Neurol. 85, 229\u2013240 (2019).","journal-title":"Ann. Neurol."},{"key":"269_CR213","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","volume":"78","author":"M Lu","year":"2021","unstructured":"Lu, M. et al. Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase III clinical trials. JAMA Neurol. 78, 445\u2013453 (2021).","journal-title":"JAMA Neurol."},{"key":"269_CR214","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","volume":"141","author":"VJ Lowe","year":"2018","unstructured":"Lowe, V. J. et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer\u2019s dementia. Brain 141, 271\u2013287 (2018).","journal-title":"Brain"},{"key":"269_CR215","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748\u2013763 (2017).","journal-title":"Brain"},{"key":"269_CR216","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw, L. M. et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 14, 1505\u20131521 (2018).","journal-title":"Alzheimers Dement."},{"key":"269_CR217","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo, J. L. et al. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol. 136, 821\u2013853 (2018).","journal-title":"Acta Neuropathol."},{"key":"269_CR218","first-page":"30029","volume":"1","author":"O Hansson","year":"2018","unstructured":"Hansson, O. et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 1, 30029\u201330023 (2018).","journal-title":"Alzheimers Dement."},{"key":"269_CR219","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson, O. et al. Prediction of Alzheimer\u2019s disease using the CSF A\u03b242\/A\u03b240 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316\u2013320 (2007).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"269_CR220","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang, J. et al. Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho-Tau in patients with low- and high-CSF A\u03b240 load. J. Neurochem. 101, 1053\u20131059 (2007).","journal-title":"J. Neurochem."},{"key":"269_CR221","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385\u2013393 (2009).","journal-title":"JAMA"},{"key":"269_CR222","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillb\u00e4ck","year":"2015","unstructured":"Skillb\u00e4ck, T. et al. Cerebrospinal fluid tau and amyloid-\u03b21-42 in patients with dementia. Brain 138, 2716\u20132731 (2015).","journal-title":"Brain"},{"key":"269_CR223","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awm140","volume":"130","author":"K Buerger","year":"2007","unstructured":"Buerger, K. et al. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain 130, e82 (2007).","journal-title":"Brain"},{"key":"269_CR224","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Sepp\u00e4l\u00e4","year":"2012","unstructured":"Sepp\u00e4l\u00e4, T. T. et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78, 1568\u20131575 (2012).","journal-title":"Neurology"},{"key":"269_CR225","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"269_CR226","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat. Commun. 11, 1683 (2020).","journal-title":"Nat. Commun."},{"key":"269_CR227","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2018.3459","volume":"76","author":"S Kern","year":"2019","unstructured":"Kern, S. et al. Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment. JAMA Neurol. 76, 187\u2013193 (2019).","journal-title":"JAMA Neurol."},{"key":"269_CR228","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2020","unstructured":"Zetterberg, H. & Bendlin, B. B. Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies. Mol. Psychiatry 26, 296\u2013308 (2020).","journal-title":"Mol. Psychiatry"},{"key":"269_CR229","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh, R. et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 73, 561\u2013571 (2016).","journal-title":"JAMA Neurol."},{"key":"269_CR230","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"269_CR231","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"269_CR232","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"269_CR233","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf, F. et al. Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study. Brain 143, 1220\u20131232 (2020).","journal-title":"Brain"},{"key":"269_CR234","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton, N. J. et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat. Rev. Neurol. 16, 265\u2013284 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"269_CR235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13195-017-0294-2","volume":"9","author":"C Wattmo","year":"2017","unstructured":"Wattmo, C. & Wallin A, K. Early- versus late-onset Alzheimer\u2019s disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimers Res. Ther. 9, 70 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"269_CR236","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1212\/WNL.0b013e3181d64786","volume":"74","author":"RS Wilson","year":"2010","unstructured":"Wilson, R. S. et al. Cognitive decline in incident Alzheimer\u2019s disease in a community population. Neurology 74, 951\u2013955 (2010).","journal-title":"Neurology"},{"key":"269_CR237","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1212\/WNL.0000000000005863","volume":"91","author":"AC van Harten","year":"2018","unstructured":"van Harten, A. C. et al. Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging. Neurology 91, e300\u2013e312 (2018).","journal-title":"Neurology"},{"key":"269_CR238","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1212\/WNL.0000000000000856","volume":"83","author":"RJ Kryscio","year":"2014","unstructured":"Kryscio, R. J. et al. Self-reported memory complaints: implications from a longitudinal cohort with autopsies. Neurology 83, 1359\u20131365 (2014).","journal-title":"Neurology"},{"key":"269_CR239","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.bp.110.078683","volume":"198","author":"R Stewart","year":"2011","unstructured":"Stewart, R. et al. Longitudinal neuroimaging correlates of subjective memory impairment: 4-year prospective community study. Br. J. Psychiatry 198, 199\u2013205 (2011).","journal-title":"Br. J. Psychiatry"},{"key":"269_CR240","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.neuropsychologia.2012.08.011","volume":"50","author":"RE Amariglio","year":"2012","unstructured":"Amariglio, R. E. et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50, 2880\u20132886 (2012).","journal-title":"Neuropsychologia"},{"key":"269_CR241","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/WNL.0000000000003907","volume":"88","author":"RC Petersen","year":"2017","unstructured":"Petersen, R. C. et al. Randomized controlled trials in mild cognitive impairment: sources of variability. Neurology 88, 1751\u20131758 (2017).","journal-title":"Neurology"},{"key":"269_CR242","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","volume":"75","author":"RO Roberts","year":"2018","unstructured":"Roberts, R. O. et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 75, 970\u2013979 (2018).","journal-title":"JAMA Neurol."},{"key":"269_CR243","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","volume":"138","author":"SJ Vos","year":"2015","unstructured":"Vos, S. J. et al. Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage. Brain 138, 1327\u20131338 (2015).","journal-title":"Brain"},{"key":"269_CR244","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack Jr.","year":"2019","unstructured":"Jack, C. R. Jr. et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321, 2316\u20132325 (2019).","journal-title":"JAMA"},{"key":"269_CR245","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/brain\/awz025","volume":"142","author":"DS Knopman","year":"2019","unstructured":"Knopman, D. S. et al. Entorhinal cortex tau, amyloid-\u03b2, cortical thickness and memory performance in non-demented subjects. Brain 142, 1148\u20131160 (2019).","journal-title":"Brain"},{"key":"269_CR246","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"SJ Vos","year":"2013","unstructured":"Vos, S. J. et al. Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12, 957\u2013965 (2013).","journal-title":"Lancet Neurol."},{"key":"269_CR247","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/ana.24369","volume":"77","author":"A Serrano-Pozo","year":"2015","unstructured":"Serrano-Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A. & Hyman, B. T. APOE\u03b52 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 77, 917\u2013929 (2015).","journal-title":"Ann. Neurol."},{"key":"269_CR248","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1212\/WNL.51.1.149","volume":"51","author":"S Craft","year":"1998","unstructured":"Craft, S. et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer\u2019s disease. Neurology 51, 149\u2013153 (1998).","journal-title":"Neurology"},{"key":"269_CR249","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7326\/M17-1530","volume":"168","author":"M Butler","year":"2018","unstructured":"Butler, M. et al. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann. Intern. Med. 168, 52\u201362 (2018).","journal-title":"Ann. Intern. Med."},{"key":"269_CR250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/M17-1529","volume":"168","author":"HA Fink","year":"2018","unstructured":"Fink, H. A. et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann. Intern. Med. 168, 39\u201351 (2018).","journal-title":"Ann. Intern. Med."},{"key":"269_CR251","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M17-1528","volume":"168","author":"M Brasure","year":"2018","unstructured":"Brasure, M. et al. Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia: a systematic review. Ann. Intern. Med. 168, 30\u201338 (2018).","journal-title":"Ann. Intern. Med."},{"key":"269_CR252","unstructured":"Kane, R. L. et al. in Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer\u2019s-Type Dementia (Agency for Healthcare Research and Quality, 2017)."},{"key":"269_CR253","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu, T. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 2255\u20132263 (2015). A first demonstration of non-pharmacological means of delaying cognitive decline in elderly persons at risk for dementia.","journal-title":"Lancet"},{"key":"269_CR254","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1212\/WNL.0b013e318227b227","volume":"77","author":"S Debette","year":"2011","unstructured":"Debette, S. et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77, 461\u2013468 (2011).","journal-title":"Neurology"},{"key":"269_CR255","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"Williamson, J. D. et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA 321, 553\u2013561 (2019).","journal-title":"JAMA"},{"key":"269_CR256","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/jgs.16862","volume":"68","author":"DB Reuben","year":"2020","unstructured":"Reuben, D. B. et al. D-CARE: the dementia care study: design of a pragmatic trial of the effectiveness and cost effectiveness of health system-based versus community-based dementia care versus usual dementia care. J. Am. Geriatr. Soc. 68, 2492\u20132499 (2020).","journal-title":"J. Am. Geriatr. Soc."},{"key":"269_CR257","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jalz.2007.07.008","volume":"3","author":"JD Fisk","year":"2007","unstructured":"Fisk, J. D., Beattie, B. L., Donnelly, M., Byszewski, A. & Molnar, F. J. Disclosure of the diagnosis of dementia. Alzheimers Dement. 3, 404\u2013410 (2007).","journal-title":"Alzheimers Dement."},{"key":"269_CR258","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-020-00476-4","volume":"21","author":"Z Alpinar-Sencan","year":"2020","unstructured":"Alpinar-Sencan, Z. & Schicktanz, S. Addressing ethical challenges of disclosure in dementia prediction: limitations of current guidelines and suggestions to proceed. BMC Med. Ethics 21, 33 (2020).","journal-title":"BMC Med. Ethics"},{"key":"269_CR259","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1017\/S1041610215001830","volume":"28","author":"H Amieva","year":"2016","unstructured":"Amieva, H. et al. Group and individual cognitive therapies in Alzheimer\u2019s disease: the ETNA3 randomized trial. Int. Psychogeriatr. 28, 707\u2013717 (2016).","journal-title":"Int. Psychogeriatr."},{"key":"269_CR260","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2017.15006","volume":"318","author":"AC Tricco","year":"2017","unstructured":"Tricco, A. C. et al. Comparisons of interventions for preventing falls in older adults: a systematic review and meta-analysis. JAMA 318, 1687\u20131699 (2017).","journal-title":"JAMA"},{"key":"269_CR261","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","volume":"57","author":"RC Mohs","year":"2001","unstructured":"Mohs, R. C. et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57, 481\u2013488 (2001).","journal-title":"Neurology"},{"key":"269_CR262","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza, F., Lozupone, M., Logroscino, G. & Imbimbo, B. P. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73\u201388 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"269_CR263","unstructured":"Rogers, M. B. https:\/\/www.alzforum.org\/news\/research-news\/aducanumab-still-needs-prove-itself-researchers-say (2020)."},{"key":"269_CR264","doi-asserted-by":"publisher","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2100708 (2021).","DOI":"10.1056\/NEJMoa2100708"},{"key":"269_CR265","unstructured":"Shugart, J. https:\/\/www.alzforum.org\/news\/conference-coverage\/banish-av-ban2401-antibody-makes-its-move-phase-3-program (2020)."},{"key":"269_CR266","doi-asserted-by":"crossref","first-page":"134919","DOI":"10.1016\/j.neulet.2020.134919","volume":"731","author":"L VandeVrede","year":"2020","unstructured":"VandeVrede, L., Boxer, A. L. & Polydoro, M. Targeting tau: clinical trials and novel therapeutic approaches. Neurosci. Lett. 731, 134919 (2020).","journal-title":"Neurosci. Lett."},{"key":"269_CR267","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/alz.12109","volume":"16","author":"S Rios-Romenets","year":"2020","unstructured":"Rios-Romenets, S. et al. Baseline demographic, clinical, and cognitive characteristics of the Alzheimer\u2019s prevention initiative (API) autosomal-dominant Alzheimer\u2019s disease Colombia trial. Alzheimers Dement 16, 1023\u20131030 (2020).","journal-title":"Alzheimers Dement"},{"key":"269_CR268","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/acn3.51048","volume":"7","author":"PS Insel","year":"2020","unstructured":"Insel, P. S., Donohue, M. C., Sperling, R., Hansson, O. & Mattsson-Carlgren, N. The A4 study: \u03b2-amyloid and cognition in 4432 cognitively unimpaired adults. Ann. Clin. Transl. Neurol. 7, 776\u2013785 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"269_CR269","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"Ballard, C. et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 17, 213\u2013222 (2018).","journal-title":"Lancet Neurol."},{"key":"269_CR270","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11136-016-1471-7","volume":"26","author":"LA Jennings","year":"2017","unstructured":"Jennings, L. A. et al. Patient and caregiver goals for dementia care. Qual. Life Res. 26, 685\u2013693 (2017).","journal-title":"Qual. Life Res."},{"key":"269_CR271","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/gnaa169","author":"S Bannon","year":"2020","unstructured":"Bannon, S. et al. In it together: a qualitative meta-synthesis of common and unique psychosocial stressors and adaptive coping strategies of persons with young-onset dementia and their caregivers. Gerontologist https:\/\/doi.org\/10.1093\/geront\/gnaa169 (2020).","journal-title":"Gerontologist"},{"key":"269_CR272","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1177\/1471301212447026","volume":"12","author":"H Moon","year":"2013","unstructured":"Moon, H. & Adams, K. B. The effectiveness of dyadic interventions for people with dementia and their caregivers. Dementia 12, 821\u2013839 (2013).","journal-title":"Dementia"},{"key":"269_CR273","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","volume":"388","author":"EP van Charante","year":"2016","unstructured":"van Charante, E. P. et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet 388, 797\u2013805 (2016).","journal-title":"Lancet"},{"key":"269_CR274","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","volume":"16","author":"S Andrieu","year":"2017","unstructured":"Andrieu, S. et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 16, 377\u2013389 (2017).","journal-title":"Lancet Neurol."},{"key":"269_CR275","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2015.9617","volume":"314","author":"KM Sink","year":"2015","unstructured":"Sink, K. M. et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the life randomized trial. JAMA 314, 781\u2013790 (2015).","journal-title":"JAMA"},{"key":"269_CR276","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41593-018-0240-z","volume":"21","author":"PL De Jager","year":"2018","unstructured":"De Jager, P. L., Yang, H. S. & Bennett, D. A. Deconstructing and targeting the genomic architecture of human neurodegeneration. Nat. Neurosci. 21, 1310\u20131317 (2018).","journal-title":"Nat. Neurosci."},{"key":"269_CR277","doi-asserted-by":"crossref","first-page":"101066","DOI":"10.1016\/j.arr.2020.101066","volume":"60","author":"SH Rehiman","year":"2020","unstructured":"Rehiman, S. H. et al. Proteomics as a reliable approach for discovery of blood-based Alzheimer\u2019s disease biomarkers: a systematic review and meta-analysis. Ageing Res. Rev. 60, 101066 (2020).","journal-title":"Ageing Res. Rev."},{"key":"269_CR278","volume":"17","author":"UV Mahajan","year":"2020","unstructured":"Mahajan, U. V. et al. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: a targeted metabolomic and transcriptomic study. PLoS Med. 17, e1003012 (2020).","journal-title":"PLoS Med."},{"key":"269_CR279","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","volume":"21","author":"TM Dawson","year":"2018","unstructured":"Dawson, T. M., Golde, T. E. & Lagier-Tourenne, C. Animal models of neurodegenerative diseases. Nat. Neurosci. 21, 1370\u20131379 (2018).","journal-title":"Nat. Neurosci."},{"key":"269_CR280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.stem.2018.12.013","volume":"24","author":"R van der Kant","year":"2019","unstructured":"van der Kant, R. et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-\u03b2 in iPSC-derived Alzheimer\u2019s disease neurons. Cell Stem Cell 24, 363\u2013375.e9 (2019).","journal-title":"Cell Stem Cell"},{"key":"269_CR281","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. DSM-5: Diagnostic and Statistical Manual of Mental Disorders 5th ed. (American Psychiatric Association, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"269_CR282","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"M Albert","year":"2011","unstructured":"Albert, M. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013 Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 7, 270\u2013279 (2011).","journal-title":"Alzheimer\u2019s Dement."},{"key":"269_CR283","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 13, 614\u2013629 (2014).","journal-title":"Lancet Neurol."},{"key":"269_CR284","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791\u20131800 (2002).","journal-title":"Neurology"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00269-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00269-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00269-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T19:30:08Z","timestamp":1670009408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00269-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":284,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1038\/s41572-021-00269-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740108954.793591159","asserted-by":"object"}]},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"9 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S.K. served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen but receives no personal compensation. He is a site investigator in a Biogen aducanumab trial. He is an investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock, Roche and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH. G.C. serves on the Scientific Advisory Board of the Fondation Vaincre Alzheimer but receives no personal compensation. She receives personal fees from Fondation d\u2019entreprise MMA des Entrepreneurs du Futur and from Fondation Alzheimer as she serves in the Operational Committee. She receives research support from European Union Horizon 2020 research and innovation programme (grant agreement number 667696), Inserm, Fondation d\u2019entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, R\u00e9gion Normandie, Association France Alzheimer et maladies apparent\u00e9es and Fondation Vaincre Alzheimer. R.C.P. is a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc. and Eisai, Inc., has given educational lectures for GE Healthcare, receives publishing royalties from <i>Mild Cognitive Impairment<\/i> (Oxford University Press, 2003), UpToDate, and receives research support from the NIH. B.T.H. has a family member who works at Novartis and owns stock in Novartis; he serves on the SAB of Dewpoint and owns stock. He serves on a scientific advisory board or is a consultant for Biogen, Novartis, Cell Signalling, the US Dept of Justice, Takeda, Vigil, W20 group and Seer. His laboratory is supported by sponsored research agreements with Abbvie, F Prim, and research grants from the National Institutes of Health, Cure Alzheimer\u2019s Fund, Tau Consortium, Brightfocus and the JPB Foundation. H.A. serves on the Scientific Advisory Board of the Observatoire des M\u00e9moires but receives no personal compensation. She receives research support from Spoelberch Foundation, Association France Alzheimer et maladies apparent\u00e9es, the Regional Health Agency of Aquitaine and National Research Agency. D.M.H. reports being a Co-founder for C2N Diagnostics LLC and participating in scientific advisory boards\/consulting for Genentech, C2N Diagnostics, Denali, Merck and Idorsia. He is an inventor on patents licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies (this anti-tau antibody programme is licensed to Abbvie) and to Eli Lilly on the therapeutic use of an anti-amyloid-\u03b2 antibody. His laboratory receives research grants from the National Institutes of Health, Cure Alzheimer\u2019s Fund, Tau Consortium, the JPB Foundation, Good Ventures, Centene, BrightFocus and C2N Diagnostics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}